Esomeprazole/naproxen - Aralez Pharmaceuticals/AstraZeneca

Drug Profile

Esomeprazole/naproxen - Aralez Pharmaceuticals/AstraZeneca

Alternative Names: esomeprazole magnesium trihydrate/naproxen; Naproxen/esomeprazole; naproxen/esomeprazole magnesium trihydrate; PN-400; Vimovo

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Cincinnati Children's Hospital Medical Center; POZEN
  • Developer Aralez Pharmaceuticals Inc.; AstraZeneca; Horizon Pharma
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis
  • Clinical Phase Unknown Juvenile rheumatoid arthritis

Most Recent Events

  • 30 Oct 2018 AstraZeneca's marketing agreement with Grünenthal for global commercialisation rights (excluding USA and Japan) to esomeprazole/naproxen is expected to close in December 2018
  • 30 Oct 2018 Grünenthal agrees to acquire global exclusive rights to market esomeprazole/naproxen excluding USA and Japan markets (9252940; 9252885)
  • 10 Aug 2018 Aralez Pharmaceuticals enter into stalking-horse purchase agreement with Nuvo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top